Format

Send to

Choose Destination
Iran J Cancer Prev. 2015 May;8(3):e2326. doi: 10.17795/ijcp2326. Epub 2015 May 22.

An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant.

Author information

1
Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

Abstract

BACKGROUND:

Today, Lack of efficient therapeutic strategy for breast cancer (the most common cause of death in women) is one of the momentous problematic topics for all health care committees. Designing new specific vaccine, based on antigens located on the surface of cancer cells can be useful. Over expression of ROR1, lacked of HER2/neu, and hormone receptors on cell surface in the breast cancer, introduce this protein as an appropriate candidate for designing cancer vaccine.

OBJECTIVES:

We hypothesized the extracellular domain of receptor tyrosine kinase like orphan receptor 1 (ROR-1) along with a super antigen such as staphylococcal enterotoxin B could be a potent vaccine for drug resistant breast cancer.

MATERIALS AND METHODS:

Here, we assessed the findings of bioinformatics analysis to identify the antitumor immune properties of this chimeric construct. In addition, the stability, physic-chemical properties and allergic potency of designed fusion protein were investigated by valid bioinformatics software.

RESULTS:

Our result suggested that chimeric model is capable to be a stimulant of both T-cell and B- cell mediated immune responses with an acceptable accessibility and solubility but without any allergenicity.

CONCLUSIONS:

The ROR-1 with an enterotoxin B could be a potent vaccine for breast cancer.

KEYWORDS:

Breast Neoplasms; ROR-1; Staphylococcus Entorotoxin B; Vaccines

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center